Approximately a quarter of men with metastatic castrate resistant prostate cancer (mCRPC) have alterations in homologous recombination repair (HRR). These patients exhibit enhanced sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors. Leveraging the synthetic lethality between PARP inhibition and HRR deficiency, studies have established marked clinical benefit and a survival advantage from PARP inhibitors (PARPi) in mCRPC, most notably in cancers with BRCA1/2 alterations. The role of PARPi is evolving beyond patients with HRR alterations, with studies increasingly focused on exploiting synergistic effects from combination therapeutics. Strategies combining PARP inhibitors with androgen receptor pathway inhibitors, radiation, radioligand therapy, chemotherapy and immunotherapy demonstrate potential additional benefits in mCRPC and these approaches are rapidly moving into the metastatic hormone sensitive treatment paradigm. In this review we summarise the development and expanding role of PARPi in prostate cancer including biomarkers of response, the relationship between the androgen receptor and PARP, evidence for combination therapeutics and the future directions of PARPi in precision medicine for prostate cancer.
Mitchell G. Lawrence, Laura H. Porter, Nicholas Choo, Elaine Sanij, Renea A. Taylor, Richard B. Pearson, Kaylene J. Simpson, Ross D. Hannan, Shahneen Sandhu, Luc Furic
Carmel Pezaro, Shahneen Sandhu, Susanne Ramm, Jennii Luu, Andrew Bakshi, David L. Goode, Elaine Sanij, Richard B. Pearson, Ross D. Hannan, Kaylene J. Simpson, Renea A. Taylor, Gail P. Risbridger, Luc Furic, Mitchell G. Lawrence, Laura H. Porter, Nicholas Choo, David Pook, Jeremy Grummet
Discussion(0)
No comments yet. Be the first to comment.